Actinogen Medical Ltd: Actinogen receives $9.0 million R&D tax incentive rebate
Actinogen Medical Ltd: Annual Report to Shareholders
Actinogen Medical Ltd: ACW FY2024 results, advancing into late-stage trials
Actinogen Medical Ltd: ACW Appendix 4E and 2024 Annual Report
Actinogen Medical Ltd: Actinogen HY2024 financial results two key phase 2 trial
Actinogen Medical Ltd: Actinogen HY2024 financial report and Appendix 4D
Actinogen Medical Ltd: Annual Report to Shareholders
Actinogen Medical Ltd: Actinogen FY2023 results, following the science
Actinogen Medical Ltd: ACW Appendix 4E and 2023 Annual Report
Actinogen Medical Ltd: Appendix 4D & Half-Year Financial Statements
Actinogen Medical Ltd: Annual Report to Shareholders
Actinogen Medical Ltd: Actinogen FY22 Results - Accelerating Clinical Development
Actinogen Medical Ltd: ACW Appendix 4E and 2022 Annual Report
Actinogen Medical Ltd: Appendix 4D & Half-Year Financial Statements
Actinogen Medical Ltd: Annual Report to Shareholders
Actinogen Medical Ltd: Actinogen Medical FY21 Results- Progressing the Pipeline
Actinogen Medical Ltd: Appendix 4E & Annual Report
Actinogen Medical Ltd: Appendix 4D & Half-Year Financial Statements
Actinogen Medical Ltd: Annual Report to Shareholders
Actinogen Medical Ltd: Appendix 4E & Annual Report